SCHEMBL512793

SCHEMBL512793

C#CC=C1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 1/20 0.53
USP2 O75604 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HPGD P15428 1/20 0.43
ESR2 Q92731 1/20 0.42
RECQL P46063 1/20 0.41
ADORA1 P30542 1/20 0.41
PTPN2 P17706 1/20 0.41
PTPN1 P18031 1/20 0.41
PTPN6 P29350 1/20 0.41
NR1H2 P55055 1/20 0.41
DDB1 Q16531 1/20 0.40
CRBN Q96SW2 1/20 0.40
GPR119 Q8TDV5 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
EPHX1 P07099 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16493969 0.91 ESR2 (0.46) GRM5USP2SMN1; SMN2HPGDESR2
SCHEMBL16493968 0.91 ESR2 (0.46) GRM5USP2SMN1; SMN2HPGDESR2
SCHEMBL99227 0.84 GRM5 (0.53) GRM5USP2SMN1; SMN2HPGDESR2
SCHEMBL24673913 0.80 USP2 (0.51) GRM5USP2SMN1; SMN2HPGDESR2
SCHEMBL10253506 0.80 USP2 (0.51) GRM5USP2SMN1; SMN2HPGDESR2
SCHEMBL20660281 0.80 GRM5 (0.49) GRM5USP2SMN1; SMN2HPGDESR2
SCHEMBL20660282 0.80 GRM5 (0.49) GRM5USP2SMN1; SMN2HPGDESR2
SCHEMBL513283 0.80 GRM5 (0.61) GRM5USP2SMN1; SMN2ESR2RECQL
SCHEMBL30897992 0.79 USP2 (0.50) GRM5USP2SMN1; SMN2HPGDESR2
SCHEMBL513246 0.79 USP2 (0.50) GRM5USP2SMN1; SMN2HPGDESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120028931-A1 HETEROCYCLIC M-GLU5 ANTAGONISTS RECORDATI IRELAND LIMITED (IE) 2012-02-02 US disclosed
EP-2178858-B1 NOVEL HETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS RECORDATI IRELAND LTD (IE) 2011-12-28 EP disclosed
EP-2178858-A1 NOVEL HETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS Recordati Ireland Limited (IE) 2010-04-28 EP disclosed
WO-2009015897-A1 NOVEL HETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS RECORDATI IRELAND LIMITED (IE) 2009-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028931-A1 HETEROCYCLIC M-GLU5 ANTAGONISTS OPRM1, GRM5, OPRD1 GRM5 2/4885USP2 3153/4885SMN1; SMN2 411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.